apraclonidine 10 MG/ML Ophthalmic Solution [Iopidine]

What the CMS Formulary Data Shows for apraclonidine 10 MG/ML Ophthalmic Solution [Iopidine]

Per the CMS 2026 Part D formulary file, apraclonidine 10 MG/ML Ophthalmic Solution [Iopidine] (RxNorm concept RXCUI 211020, generic name apraclonidine) appears on 16 distinct formulary files spanning 104 Medicare Part D plan offerings - 2.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 2 to Tier 4, with a cross-plan average of Tier 3.5.

Real-world access to apraclonidine 10 MG/ML Ophthalmic Solution [Iopidine] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,543 Part D beneficiaries filled apraclonidine 10 MG/ML Ophthalmic Solution [Iopidine] in 2023, with total plan-and-beneficiary spending of $320,356 and an average per-beneficiary annual cost of $207.62. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry apraclonidine 10 MG/ML Ophthalmic Solution [Iopidine] today.